CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7231 result(s)

Providing Appropriate Virtual Care Within and Beyond the Pandemic: Considerations for Policy-Makers

Event Date: May 5, 2021
Result type: Events

The COVID-19 pandemic has definitely affected many different aspects of the Canadian health care system — including the widespread adoption of virtual care. Demand for virtual care is unlikely to diminish over the immediate and long term; therefore, many people are wondering how to best optimize virtual care to ensure its sustainability and its ...

Trientine Hydrochloride (MAR-Trientine)

Last Updated: April 20, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Trientine Hydrochloride
Indications: ​MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.

  • Brand Name: MAR-Trientine
  • Manufacturer: Marcan Pharmaceuticals Inc.
  • Project Number: SR0680-000
  • Project Status: Received
  • Submission Type: Initial

upadacitinib (Rinvoq)

Last Updated: April 20, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: upadacitinib
Indications: Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs.

  • Brand Name: Rinvoq
  • Manufacturer: AbbVie
  • Project Number: SR0658-000
  • Project Status: Active
  • Submission Type: Initial

osimertinib (Tagrisso )

Last Updated: April 19, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: osimertinib
Indications: Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

  • Brand Name: Tagrisso
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0246-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: April 20, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Complete
  • Submission Type: Initial

CADTH Lecture — How to Advance Gender Equity

Event Date: April 20, 2021
Result type: Events

Despite evidence showing that greater gender equity is better for health policy-making and patient care, gender inequity remains a problem in Canadian health care. This lecture will explore the occurrence and consequences of gender inequity in medicine and academia, present why gender equity is important, and provide strategies to promote gender...

ofatumumab (Kesimpta)

Last Updated: April 19, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

  • Brand Name: Kesimpta
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-000
  • Project Status: Complete
  • Submission Type: Initial

risdiplam (Evrysdi)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

  • Brand Name: Evrysdi
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial

chlormethine hydrochloride (Ledaga)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: chlormethine hydrochloride
Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

  • Brand Name: Ledaga
  • Manufacturer: Recordati Rare Diseases Canada Inc.
  • Project Number: PC0242-000
  • Project Status: Active
  • Submission Type: Initial

Ozonated Sinks for Infection Prevention

Last Updated: April 19, 2021
Result type: Projects in Progress
Report Type: Summary of Abstracts

This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects...